Serum FGF21 as a predictor of hepatic steatosis severity in non-alcoholic fatty liver disease: an integrated molecular and clinical analysis.
The aim of this paper is to assess serum fibroblast growth factor 21 (FGF21) concentration as a potential biomarker for hepatic steatosis severity in Non-Alcoholic Fatty Liver Disease (NAFLD) through an integrated molecular and clinical approach. This retrospective study assessed 120 NAFLD patients and collected clinic...